Expression of mitochondrial TSPO and FAM173B is associated with inflammation and symptoms in patients with painful knee osteoarthritis.
Adult
Aged
Arthralgia
/ etiology
Cartilage, Articular
/ metabolism
Case-Control Studies
Chemokine CCL11
/ genetics
Chemokine CCL17
/ genetics
Chemokine CCL2
/ genetics
Female
Gene Expression
Histone-Lysine N-Methyltransferase
/ genetics
Humans
Interleukins
/ genetics
Knee Joint
/ metabolism
Male
Middle Aged
Osteoarthritis, Knee
/ genetics
RNA, Messenger
/ metabolism
Real-Time Polymerase Chain Reaction
Receptors, GABA
/ genetics
Synovial Membrane
/ metabolism
Visual Analog Scale
family with sequence similarity 173B (FAM173B)
joint pain
mitochondrial dysfunction
osteoarthritis (OA)
synovial inflammation
translocator protein (TSPO)
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
06 04 2021
06 04 2021
Historique:
received:
13
01
2020
revised:
16
07
2020
pubmed:
18
10
2020
medline:
29
6
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
To characterize the expression profiles of two nuclear-encoded mitochondrial genes previously associated with chronic pain, the translocator protein (TSPO) and family with sequence similarity 173B (FAM173B), in different knee compartments from patients with painful knee OA. Also, to examine their association with the joint expression of inflammatory cytokines/chemokines and clinical symptoms. The study was performed on 40 knee OA patients and 19 postmortem (PM) controls from which we collected the knee tissues: articular cartilage (AC), synovial membrane (SM) and subchondral bone (SB). Quantitative real-time polymerase chain reaction was used to determine the relative mRNA levels of TSPO, FAM173B, and inflammatory mediators IL6, IL8, IL10, IL12, MCP1, CCL11 and CCL17. OA patients rated their pain intensity (visual analogue scale), severity of knee-related outcomes (KOOS) and pain sensitivity assessed by pressure algometry. The gene expression of TSPO in SM was elevated in OA patients compared with control subjects while there were no group differences in AC and SB. Expression of FAM173B was reduced in SM but elevated in SB in OA patients compared with controls. The expression of TSPO and FAM173B in SM and SB was associated with the expression of inflammatory substances, but not in AC. Synovial expression of TSPO correlated with lower pain intensity and FAM173B with increased pressure pain sensitivity in OA. Our results suggest that altered expression of TSPO and FAM173B is associated with joint expression of inflammatory mediators and with clinical symptoms indicating the relevance for the pathophysiology of knee OA.
Identifiants
pubmed: 33067627
pii: 5927558
doi: 10.1093/rheumatology/keaa565
pmc: PMC8023995
doi:
Substances chimiques
CCL11 protein, human
0
CCL2 protein, human
0
Chemokine CCL11
0
Chemokine CCL17
0
Chemokine CCL2
0
Interleukins
0
RNA, Messenger
0
Receptors, GABA
0
TSPO protein, human
0
ATPSCKMT protein, human
EC 2.1.1.43
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1724-1733Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Références
Arthritis Rheumatol. 2015 May;67(8):2141-53
pubmed: 25940958
Rheumatology (Oxford). 2014 Jul;53(7):1332-43
pubmed: 24609059
J Biol Chem. 2019 Jan 25;294(4):1128-1141
pubmed: 30530489
Arthritis Res Ther. 2010;12(4):R126
pubmed: 20594330
Nat Rev Rheumatol. 2017 May;13(5):302-311
pubmed: 28381830
J Orthop Sports Phys Ther. 1998 Aug;28(2):88-96
pubmed: 9699158
Brain Behav Immun. 2019 Jan;75:72-83
pubmed: 30223011
Nat Rev Rheumatol. 2011 Mar;7(3):161-9
pubmed: 21200395
J Immunol. 2018 Oct 1;201(7):1918-1927
pubmed: 30135182
Brain Behav Immun. 2016 Nov;58:218-227
pubmed: 27448744
Nat Rev Dis Primers. 2016 Oct 13;2:16072
pubmed: 27734845
J Clin Invest. 1995 Nov;96(5):2304-10
pubmed: 7593617
Cytokine. 2007 Dec;40(3):226-34
pubmed: 18023359
J Nucl Med. 2018 Jul;59(7):1125-1132
pubmed: 29301931
J Neurosci Res. 2017 Jan 2;95(1-2):487-499
pubmed: 27870418
Arthritis. 2012;2012:741582
pubmed: 22745906
Ann Rheum Dis. 2013 Mar;72(3):427-36
pubmed: 22956598
J Rheumatol. 2002 Oct;29(10):2165-75
pubmed: 12375328
Ann N Y Acad Sci. 2006 Jun;1069:155-67
pubmed: 16855143
Curr Mol Med. 2012 May;12(4):426-42
pubmed: 22348611
Brain Behav Immun. 2019 Jan;75:60-71
pubmed: 30248387
Mediators Inflamm. 2014;2014:561459
pubmed: 24876674
Brain Behav Immun. 2016 Oct;57:38-46
pubmed: 27058164
Mol Cell Biochem. 2014 Dec;397(1-2):195-201
pubmed: 25129057
J Neurosci Res. 2017 Jan 2;95(1-2):500-508
pubmed: 27870397
Arthritis Rheum. 2012 Sep;64(9):2927-36
pubmed: 22549761
Biochem Soc Trans. 2015 Aug;43(4):543-52
pubmed: 26551691
J Biol Chem. 2019 Aug 2;294(31):11654-11664
pubmed: 31213526
Brain. 2015 Mar;138(Pt 3):604-15
pubmed: 25582579
Cytokine. 2014 Dec;70(2):185-93
pubmed: 25066335
Brain Behav Immun. 2015 May;46:35-43
pubmed: 25486090
Nat Rev Rheumatol. 2016 Jul;12(7):412-20
pubmed: 27192932
Osteoarthritis Cartilage. 2018 Aug;26(8):989-991
pubmed: 29857157
Neuro Oncol. 2020 Feb 20;22(2):240-252
pubmed: 31563962
BMC Musculoskelet Disord. 2013 Aug 09;14:235
pubmed: 23937653
Scand J Rehabil Med. 1993 Sep;25(3):117-24
pubmed: 8248762
J Neuroimmunol. 2018 Aug 15;321:49-60
pubmed: 29957388
PLoS Biol. 2018 Feb 14;16(2):e2003452
pubmed: 29444090
Health Qual Life Outcomes. 2003 May 25;1:17
pubmed: 12801417
J Clin Invest. 2019 Mar 1;129(3):1076-1093
pubmed: 30530994
Osteoarthritis Cartilage. 2010 Mar;18(3):424-32
pubmed: 19822235
Front Mol Neurosci. 2017 Nov 03;10:349
pubmed: 29163027
Pain. 2018 May;159(5):968-977
pubmed: 29419657
PLoS One. 2017 Oct 2;12(10):e0185767
pubmed: 28968465